Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Synaptogenix is a biotechnology business based in the US. Synaptogenix shares (SNPX) are listed on the NASDAQ and all prices are listed in US Dollars. Synaptogenix employs 4 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
eToro
Finder Award
SoFi Invest
| Latest market close | $1.05 |
|---|---|
| 52-week range | $0.96 - $10.65 |
| 50-day moving average | $3.65 |
| 200-day moving average | $5.78 |
| Wall St. target price | $14.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.12 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.05 from 2023-01-25
| 1 week (2023-01-19) | -4.55% |
|---|---|
| 1 month (2022-12-23) | -10.26% |
| 3 months (2022-10-26) | -84.76% |
| 6 months (2022-07-26) | -80.63% |
| 1 year (2022-01-26) | -86.11% |
|---|---|
| 2 years (2021-01-26) | -81.90% |
| 3 years (2020-01-22) | N/A |
| 5 years (2018-01-22) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -30.32% |
| Return on equity TTM | -49.27% |
| Profit margin | 0% |
| Book value | $3.90 |
| Market capitalisation | $7.7 million |
TTM: trailing 12 months
We're not expecting Synaptogenix to pay a dividend over the next 12 months.
Synaptogenix's shares were split on a 1:4 basis on 19 May 2021. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Synaptogenix shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Synaptogenix shares which in turn could have impacted Synaptogenix's share price.
Over the last 12 months, Synaptogenix's shares have ranged in value from as little as $0.96 up to $10.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Synaptogenix's is 1.8816. This would suggest that Synaptogenix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
We explore some of the best brokerage accounts for international stock trading. Here’s what you need to know.
